February 7, 2022 2:24 pm
Published by jonas
Redwood Pharma has received approval from an Austrian ethics committee for the start of a clinical trial of RP501. This... View Article
January 24, 2022 1:52 pm
Published by jonas
Redwood Pharma will be attending two of the leading international conferences in ophthalmology and biotechology during 2022. The goals of... View Article
December 16, 2021 11:11 am
Published by jonas
Redwood Pharma extends its reach into the medical technology arena with the broadening of its development programs with the RP501... View Article
October 25, 2021 8:50 am
Published by jonas
Redwood Pharma announces today a strategic move to accelerate development of RP501, the company’s IntelliGel-based topical first-line therapy for dry... View Article
August 27, 2021 8:29 am
Published by jonas
NASDAQ FIRST NORTH GROWTH MARKET:REDW.ST, REDWOODPHARMA.COM Redwood Pharma AB (publ) Quarterly report January–June 2021 Period 1 January–30 June 2021 The... View Article
March 22, 2021 8:00 am
Published by jonas
The results of Redwood Pharma’s Phase II study of RP101 have now been published in the medical journal Advances in... View Article
February 11, 2021 10:49 pm
Published by jonas
Redwood Pharma AB’s (“Redwood Pharma” or “the Company”) new issue of shares with preferential rights for shareholders (the “Rights Issue”)... View Article
January 20, 2021 11:00 am
Published by jonas
Redwood Pharma AB (publ) (“Redwood Pharma” or “the Company”) has arranged information presentations in connection with the Company’s rights issue with a subscription period 25... View Article
January 18, 2021 9:01 am
Published by jonas
The Board of Directors of Redwood Pharma AB (publ) (“Redwood Pharma” or “the Company”) today announces its intention to switch stock exchanges from... View Article
December 29, 2020 8:00 am
Published by jonas
RP101 demonstrates treatment difference versus control (Intelligel vehicle) in inferior corneal staining with robust and significant improvement SANDE symptom score... View Article